Loading
Gestational Diabetes Research and Management / Ovarian Function and Disorders / Regulation of Appetite and Obesity · Review
Quality in Sport · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a narrative literature review summarizing reported effects of GLP-1 receptor agonists on reproductive outcomes in women with PMOS, including improvements in body weight, hormonal parameters, menstrual regularity, and pregnancy and ovulation rates. The authors conclude GLP-1 RAs may be a valuable therapeutic strategy but explicitly acknowledge that further studies—particularly safety data in the preconception period—are required before firm recommendations can be made.
Narrative literature review. Literature on women with PMOS and use of GLP-1 receptor agonists; no restriction on study design or geography stated.. Intervention: GLP-1 receptor agonists (GLP-1 RAs).
GLP-1 RAs decrease body weight and improve metabolic and hormonal parameters in patients with PMOS GLP-1 RAs contribute to restoring hypothalamus–pituitary–ovarian axis function GLP-1 RAs improve menstrual regularity in women with PMOS
Authors explicitly state further studies required; preconception safety evidence not yet available
Clinicians should recognize GLP-1 RAs as an emerging consideration for fertility restoration in obese women with PMOS, but current evidence is insufficient to change practice. Preconception safety data are needed before routine recommendation.
Narrative review synthesizing observational and clinical evidence on an emerging application; no primary data, no meta-analysis, and authors acknowledge need for further safety and efficacy studies.
As stated by the source record.
Clinicians should recognize GLP-1 RAs as an emerging consideration for fertility restoration in obese women with PMOS, but current evidence is insufficient to change practice. Preconception safety data are needed before routine recommendation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background. The Polyendocrine Metabolic Ovarian Syndrome (PMOS), previously named as Polycystic Ovary Syndrome (PCOS) is common endocrine and metabolic disorder. It is the main cause of female infertility. The manifestation is heterogeneous and contain coexisting hyperandrogenism, obesity, insulin resistance. The PMOS‑associated infertility treatment is multidisciplinary process involving pharmacotherapy, diet and lifestyle changes. Synthetic analogues of endogenous GLP-1 (GLP-1 Ras) are register for treatment of type 2 diabetes and obesity. Aim. This study aimed to assess the effectiveness of GLP‑1 RAs in improving reproductive outcomes in women with PMOS. Material and methods. Narrative literature review was conducted through a search of electronic databases: PubMed and Google Scholar. The search covered clinical trials, observational studies and articles from 2020–2026 and used combinations of the following keywords: “polycystic ovary syndrome”, “GLP 1 analogues”, ”infertility” and related terms. Additional articles were identified by screening reference lists of key publications. Results. Clinical study revealed that GLP-1 Ras decrease body weight as well as improve metabolic) and hormonal parameters in patients with PMOS. GLP-1 Ras contribute to restoring the function of the hypothalamus–pituitary–ovarian axis. In addition, their improve menstrual regularity, in women with PMOS as well as pregnancy and ovulation rates. GLP‑1 RAs may enhance spontaneous and IVF pregnancy and ovulation rates and exert suppression of pro-inflammatory agents and recovering maternal-fetal immune tolerance. Conclusions. Collectively, the broad metabolic, hormonal and immunometabolic effects of GLP‑1 RAs make them a valuable therapeutic strategy for improving fertility outcomes in obese women with PMOS, although the further studies are required—particularly those assessing their safety during the preconception period.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.